E22. ISSVD Terminology for Vulvar Intraepithelial Neoplasia (VIN) and Squamos Intraepithelial Lesions (SIL) (audio)

E22. ISSVD Terminology for Vulvar Intraepithelial Neoplasia (VIN) and Squamos Intraepithelial Lesions (SIL) (audio)

In this episode of Talking O&G: a RANZCOG Podcast, host Dr Anna Clare speaks with Conj A/Prof Tania Day about gynaecologists' role in prevention of vulvar squamous cell carcinoma by identifying and treating vulvar intraepithelial neoplasia (VIN) and distinguishing these from benign squamous intraepithelial lesions (SIL). They unpack the recently published 2026 International Society for the Study of Vulvovaginal Disease (ISSVD) terminology guide, on which Conj A/Prof Day was lead author.   The ISSVD terminology was last updated in 2015, and there have since been major advancements in the clinical understanding of VIN histopathology and immunohistochemistry. Dr Clare and Conj A/Prof Day examine these developments, outlining the new preferred terminology, as well as diagnosis, treatment, and follow up. They highlight the importance of consistent language to aid collective efforts in vulval cancer elimination.   🔗 Resources mentioned in this episode:  * 2026 International Society for the Study of Vulvovaginal Disease (ISSVD) terminology for vulvar intraepithelial neoplasia and squamous intraepithelial lesions [https://www.ajog.org/article/S0002-9378(26)00290-5/fulltext]  📌 RANZCOG members can submit CPD at: https://shorturl.at/iq733 [https://shorturl.at/iq733]   💬 If you found this episode valuable, please rate, review, subscribe, and share it with your colleagues.  RANZCOG acknowledges the need for more inclusive terminology for gender diversity. In this podcast we aim to use inclusive language, and any use of the term “women” should be interpreted to include all people requiring gynaecological and obstetric care.    The views expressed are those of the speakers and may not reflect the official position of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG).

E21. Unpacking RANZCOG’s Intrapartum Fetal Surveillance Clinical Guideline (audio)

In this episode of Talking O&G: a RANZCOG Podcast, host A/Prof Scott White speaks to Dr Penny Sheehan about RANZCOG’s updated binational clinical guideline for Intrapartum Fetal Surveillance (C-Obs 1).   They discuss recommendations for antenatal and intrapartum risk factors and models of care, cases involving fetal sepsis, the use of tocolysis in cases of prolonged deceleration, and more. They look at the evidence around alternative methods for fetal assessment, such as fetal scalp stimulation and fetal blood sampling, and new and emerging technologies.   The broader process of the guideline development is also explored, including the implementation of the GRADE system to assess evidence, and the guiding principles of care addressed in the guideline.  🔗 Resources mentioned in this episode:  * Intrapartum Fetal Surveillance (C-Obs 1) Clinical Guideline [https://ranzcog.edu.au/wp-content/uploads/Intrapartum-Fetal-Surveillance.pdf]  * Respectful Maternity and Newborn Care Framework [https://www.safercare.vic.gov.au/publications/respectful-maternity-and-newborn-care-framework]  * Fetal Surveillance Education Program (FSEP) [https://fsep.ranzcog.edu.au/]  📌 RANZCOG members can submit CPD at: https://shorturl.at/iq733 [https://shorturl.at/iq733]   💬 If you found this episode valuable, please rate, review, subscribe, and share it with your colleagues.  RANZCOG acknowledges the need for more inclusive terminology for gender diversity. In this podcast we aim to use inclusive language, and any use of the term “women” should be interpreted to include all people requiring gynaecological and obstetric care.    The views expressed are those of the speakers and may not reflect the official position of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG).

E20. Recommendations for Multidisciplinary Treatment of Persistent Pelvic Pain (audio)

In this episode of Talking O&G: a RANZCOG Podcast, host Dr Heather Waterfall speaks with Dr Marilla Druitt about multidisciplinary management and treatment options for persistent pelvic pain.   Pelvic pain affects one in five women in Australia and up to one in four women in Aotearoa New Zealand at some point in their life. Contributors are broad, and may include conditions such endometriosis or adenomyosis, antenatal or postpartum pain, or irritable bowel syndrome.  Dr Waterfall and Dr Druitt address a range of treatment and prevention approaches, including hormonal treatment, physiotherapy, pain psychology, nutrition, and more. They highlight the biopsychosocial components of pelvic pain and its comorbidities and recommend a holistic approach to care. They also emphasise the importance of focusing on prevention, to reduce the potential development of severe pain.  This episode was recorded in February 2026. Please refer to the PBS website [https://www.pbs.gov.au/pbs/home] for up-to-date information on medication availability and subsidies.   🔗 Resources mentioned in this episode:  * Australian Living Evidence Guideline: Endometriosis [https://ranzcog.edu.au/wp-content/uploads/Endometriosis-Clinical-Practice-Guideline.pdf]   * Pelvic Pain Foundation of Australia: Stretches, Strategies and Acupressure Guides [https://www.pelvicpain.org.au/ppep-talk-hub/stretches]  * Queensland Government Flowchart: Acute presentation of persistent pelvic pain [https://www.health.qld.gov.au/__data/assets/pdf_file/0025/1364416/f-acute-persistent-pelvic-pain.pdf]  * Greene Climacteric Scale [https://hub.menopause.org.au/Play?pId=889f06fe-8b48-4140-9cac-a828400d7ea8]  📌 RANZCOG members can submit CPD at: https://shorturl.at/iq733 [https://shorturl.at/iq733]   💬 If you found this episode valuable, please rate, review, subscribe, and share it with your colleagues.  RANZCOG acknowledges the need for more inclusive terminology for gender diversity. In this podcast we aim to use inclusive language, and any use of the term “women” should be interpreted to include all people requiring gynaecological and obstetric care.    The views expressed are those of the speakers and may not reflect the official position of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG).

E19. Unpacking the Clinical Utility of Maternal TORCH Screening in Fetal Growth Restriction (audio)

In this episode of Talking O&G: a RANZCOG Podcast, host Dr Nisha Khot speaks with Professor Lisa Hui and Associate Professor Natasha Holmes about the clinical utility of TORCH – Toxoplasma gondii, rubella, cytomegalovirus (CMV), and herpes simplex virus (HSV) – serology in isolated fetal growth restriction (FGR).   Professor Hui and A/Prof Holmes co-authored a study on this topic, considering whether TORCH serology should continue to be ordered for isolated FGR. They examine the importance of differentiating early- and late-onset FGR, how their findings reflect international screening recommendations, and whether TORCH screening can be a reassuring measure for patients. They highlight the waste of resources and potential increase of maternal anxiety associated with ordering TORCH serology in situations where it is clinically unnecessary.   🔗 Resources mentioned in this episode:  * Clinical utility of maternal TORCH screening in fetal growth restriction: A retrospective two-centre study [https://obgyn.onlinelibrary.wiley.com/doi/10.1111/ajo.13802]  📌 RANZCOG members can submit CPD at: https://shorturl.at/iq733 [https://shorturl.at/iq733]   💬 If you found this episode valuable, please rate, review, subscribe, and share it with your colleagues.  RANZCOG acknowledges the need for more inclusive terminology for gender diversity. In this podcast we aim to use inclusive language, and any use of the term “women” should be interpreted to include all people requiring gynaecological and obstetric care.    The views expressed are those of the speakers and may not reflect the official position of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG).

E18. Recommendations for the Diagnosis and Treatment of Vulvovaginal Candidiasis (VVC) and Bacterial Vaginosis (BV) (audio)

In this episode of Talking O&G: a RANZCOG Podcast, host Dr Anna Clare and Conjoint Associate Professor Tania Day discuss diagnosis and treatment recommendations for vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV) – two common and impactful conditions with high recurrence rates.   Dr Clare and Conj A/Prof Day examine recent and emerging research on these conditions, unpack common myths and misconceptions, and discuss their experiences diagnosing and treating them in their clinical practice. They touch on a range of long-term management strategies including male partner treatment of BV and the role of the microbiome in both conditions.  🔗 Resources mentioned in this episode:  * Recommendations for the Diagnosis and Treatment of Vaginitis [https://www.issvd.org/resources/recommendations-for-the-diagnosis-and-treatment-of-vaginitis]  * Clinician instructions for BV partner treatment [https://www.mshc.org.au/health-professionals/bv-health-professional-info/clinician-instructions-for-bv-partner-treatment]  * Genital cutaneous candidiasis versus chronic recurrent vulvovaginal candidiasis: distinct diseases, different populations [https://journals.asm.org/doi/10.1128/cmr.00020-25]  * Nature Reviews Disease Primer: Bacterial vaginosis [https://www.nature.com/articles/s41572-025-00626-1]  📌 RANZCOG members can submit CPD at: https://shorturl.at/iq733 [https://shorturl.at/iq733]   💬 If you found this episode valuable, please rate, review, subscribe, and share it with your colleagues.  RANZCOG acknowledges the need for more inclusive terminology for gender diversity. In this podcast we aim to use inclusive language, and any use of the term “women” should be interpreted to include all people requiring gynaecological and obstetric care.    The views expressed are those of the speakers and may not reflect the official position of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists (RANZCOG).